Catalog |
name |
Description |
price |
R-R-2869 |
(S)-V-0219 hydrochloride |
(S)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 hydrochloride is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice. |
price> |
R-R-2870 |
GLP-1 receptor agonist 11 CAS No.2784590-83-4 |
GLP-1 receptor agonist 11 (compound 3)/CAS No.2784590-83-4 is an agonist of GLP Receptor. GLP-1 receptor agonist 11 can be used in the study of diseases such as diabetes and non-alc. fatty liver disease. |
price> |
R-R-2871 |
(R)-V-0219 hydrochloride |
(R)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (R)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R. |
price> |
R-R-2872 |
GLP-1 receptor agonist 10 |
GLP-1 receptor agonist 10 (compound 42) is an agonist of GLP Receptor. GLP-1 receptor agonist 10 inhibits food intake and reduces glucose excursion in mice. GLP-1 receptor agonist 10 can be used in the study of type 2 diabetes (T2DM) and obesity. |
price> |
R-R-2873 |
HAEGT CAS No.852155-81-8 |
HAEGT/CAS No.852155-81-8 is the first N-terminal 1-5 residues of glucagon like peptide-1 (GLP-1) peptide, and the sequence is His-Ala-Glu-Gly-Thr. HAEGT acts as a competitive substrate for probing prime substrate binding sites of human dipeptidyl peptidase-IV (DPP-IV) 1, in which the N-terminal His-Ala is catalyzed cleavage by DPP-IV. HAEGT can be used in the research of diabetes, obesity. |
price> |
R-R-2874 |
3-Deoxyglucosone CAS No.4084-27-9 |
3-Deoxyglucosone (3-Deoxy-D-glucosone)/CAS No.4084-27-9 is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes. |
price> |
R-R-2875 |
Albiglutide fragment TFA |
Albiglutide fragment (GLP-1 (7-36) analog) TFA is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment TFA significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies. |
price> |
R-R-2876 |
HAEGTFTSDVSSYLE CAS No.926018-57-7 |
HAEGTFTSDVSSYLE/CAS No.926018-57-7 is a polypeptide from patent CN 102920658 B. GLP-I analog contains the sequence. |
price> |
R-R-2877 |
PA-8 CAS No.878437-15-1 |
PA-8/CAS No.878437-15-1 is a potent, selective and orally active PACAP type I (PAC1) receptor antagonist. PA-8 inhibits the phosphorylation of CREB induced by PACAP in PAC1-, but not VPAC1- or VPAC2-receptor. PA-8 also inhibits PACAP-induced cAMP elevation with an IC50 of 2 nM. |
price> |
R-R-2878 |
PACAP (6-38), human, ovine, rat TFA |
PACAP (6-38), human, ovine, rat TFA is a potent PACAP receptor antagonist with IC50s of 30, 600, and 40 nM for PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2, respectively. |
price> |